
Illumina and Deerfield link arms to drive 'genomics-first' drug discovery
After years of partnering with the pharma industry, Illumina is now making its own foray into drug discovery. The DNA sequencing company is entering a 5-year collaboration with Deerfield Management to use its genomic tools and AI-driven platform to identify new therapeutic targets and bend the curve on high failure rates.
The inklings of the partnership began in 2020 when Illumina bought BlueBee, a cloud computing company which was also in contract with Deerfield at the time, Matt Nelson, VP of genetics and genomics at Deerfield Discovery and Development, told Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.